- Home
- KROS vs IRMD Comparison
KROS vs IRMD Comparison
Compare KROS & IRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KROS | IRMD |
|---|---|---|
| Founded | 2015 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 655.9M | 1.2B |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | KROS | IRMD |
|---|---|---|
| Price | $18.45 | $95.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 1 |
| Target Price | $22.20 | ★ $72.00 |
| AVG Volume (30 Days) | ★ 631.0K | 79.1K |
| Earning Date | 11-05-2025 | 02-12-2026 |
| Dividend Yield | N/A | ★ 0.71% |
| EPS Growth | N/A | ★ 13.00 |
| EPS | 1.57 | ★ 1.65 |
| Revenue | ★ $246,718,000.00 | $80,511,268.00 |
| Revenue This Year | $6,924.79 | $15.17 |
| Revenue Next Year | N/A | $10.15 |
| P/E Ratio | ★ $11.77 | $57.88 |
| Revenue Growth | ★ 37798.31 | 12.91 |
| 52 Week Low | $9.12 | $47.48 |
| 52 Week High | $22.55 | $98.53 |
Technical Indicators
Market Signals| Indicator | KROS | IRMD |
|---|---|---|
| Relative Strength Index (RSI) | 39.45 | 55.56 |
| Support Level | $19.76 | $90.92 |
| Resistance Level | $21.76 | $98.53 |
| Average True Range (ATR) | 0.77 | 2.19 |
| MACD | -0.38 | -0.55 |
| Stochastic Oscillator | 2.47 | 61.17 |
Price Performance
Historical ComparisonAbout KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About IRMD iRadimed Corporation
iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.